Phase 2 Study of DNTH103 in Generalized Myasthenia Gravis Initiated
A Phase 2 study is underway to assess DNTH103 for safety and efficacy in adults with generalized myasthenia gravis.
Asset / Drug
Drug and asset intelligence for DNTH103 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.